Centinel Spine®, LLC the leading global medical device company focused exclusively on treating cervical and lumbar spinal disease with the most complete and clinically-proven total disc replacement (TDR) technology platform in the world (prodisc®), announced a significant coverage advancement for lumbar TDR in Arizona.
The second largest commercial payer in Arizona has published updated clinical coverage criteria supporting the medically necessary use of lumbar TDR at one or two consecutive levels (L3-S1) in appropriately selected patients, using an FDA-approved device.
Because prodisc L is the only lumbar TDR device with FDA approval for two-level use, the updated coverage applies exclusively to the use of the prodisc L device. The prodisc system is designed to replace the diseased disc while allowing continued movement at the treated level, consistent with maintaining spinal segmental function when clinically appropriate.
This policy update reflects a continued national trend toward broadening access to lumbar total disc replacement based on long-term clinical evidence and surgeon experience across diverse patient populations. It is estimated that commercial coverage in the U.S. for one-level lumbar TDR has grown from 50% of covered lives in 2017 to nearly 95% today. Commercial coverage in the U.S. for two-level lumbar TDR has made tremendous strides over the last several years, now with more than 40% commercial coverage.
"This is welcome news for patients across Arizona," said Karam Moon, MD, FAANS, Neurosurgeon at SWAN Brain & Spine in Scottsdale, Arizona. "With clear coverage for one- and two-level lumbar total disc replacement, we can now have more open conversations with our patients about whether disc replacement is the right treatment for their needs. I look forward to offering this option to individuals who may benefit from it."
For more information, please visit www.CentinelSpine.com
